INTERNATIONAL MULTI DISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
eISSN 2394-6334 Impact factor: 8.854 Volume 13, issue 01 (2026)

COMPARATIVE DIAGNOSIS OF HEPATITIS B AND HEPATITIS C: CLINICAL AND LABORATORY PERSPECTIVES

H.R.Ibraximova
Sh.R.Yusupov
Sh.S.Masharipova
Sh.Z.Otajanov
O.U.Matyakubova
I.A.Artikov
R.R.Nurllayev
Urgench State Medical Institute

Background: Hepatitis B (HBV) and hepatitis C (HCV) are leading causes of chronic liver disease worldwide. Despite overlapping clinical presentations, these infections differ in virology, transmission, natural history, and response to therapy. Accurate differentiation is crucial for effective management and prevention of complications.

Aim: To provide a comprehensive review of the diagnostic strategies for HBV and HCV, emphasizing serological, molecular, and imaging methods, with a focus on differentiating features.

Methods: A literature review was conducted on peer-reviewed articles, international guidelines, and clinical case reports related to HBV and HCV diagnostics. Comparative analysis was performed to highlight distinguishing characteristics between these viruses.

Results: HBV diagnosis relies on HBsAg, HBeAg, anti-HBc, anti-HBs, and HBV DNA testing, whereas HCV diagnosis primarily uses anti-HCV antibodies and HCV RNA quantification. Imaging assists in detecting liver injury but is not virus-specific. Molecular assays enable accurate viral load monitoring, genotyping, and treatment planning. Differences in serological markers, viral kinetics, and transmission routes are key for differential diagnosis.

Conclusion: Comprehensive, integrated diagnostic strategies combining serology, molecular assays, and imaging are essential for accurate differentiation between HBV and HCV. Such an approach facilitates timely therapy, monitoring, and prevention of hepatic complications.

Keywords

Hepatitis B, Hepatitis C, viral hepatitis, serology, molecular diagnostics, comparative diagnosis

Introduction

Hepatitis B and C remain global public health challenges, contributing significantly to morbidity and mortality through chronic liver disease, cirrhosis, and hepatocellular carcinoma. HBV, a DNA virus, and HCV, an RNA virus, differ in replication mechanisms, transmission routes, and chronicity rates. HBV is often transmitted perinatally or sexually, while HCV is primarily blood-borne. Clinical manifestations overlap, including fatigue, jaundice, and elevated liver enzymes, making precise laboratory differentiation essential. Misdiagnosis can lead to inappropriate therapy, disease progression, and increased risk of complications. Globally, over 296 million individuals are living with chronic HBV infection and approximately 58 million with chronic HCV infection. Early detection and accurate differentiation directly influence patient outcomes and inform preventive strategies such as HBV vaccination.

Virology of HBV and HCV

Feature	HBV	HCV
Virus type	DNA virus	RNA virus (Flaviviridae)

Feature	HBV	HCV
	(Hepadnaviridae)	
Genome	Partially double-stranded DNA	Single-stranded RNA
Replication site	Nucleus (cccDNA)	Cytoplasm
Chronicity risk	5–10% adults; >90% neonates	55–85% of infections
Vaccine	Available	Not available
Primary transmission	Blood, sexual, vertical	Blood, IV drug use, transfusion
Oncogenic potential	Hepatocellular carcinoma risk	Hepatocellular carcinoma risk

HBV replication involves nuclear cccDNA, which can persist despite antiviral therapy, contributing to reactivation. HCV lacks a DNA phase, replicates in the cytoplasm, and chronic infection often leads to liver fibrosis and cirrhosis.

Serological Diagnostics

Hepatitis B:

- **HBsAg**: Marker of infection; persistent positivity indicates chronic infection.
- **HBeAg**: Reflects active viral replication.
- **Anti-HBc (IgM/IgG)**: IgM indicates recent infection; IgG reflects past exposure.
- **Anti-HBs**: Indicates immunity (post-infection or vaccination).

Hepatitis C:

- **Anti-HCV antibodies**: Used for initial screening; cannot distinguish active from past infection.
- **HCV RNA**: Confirms active infection and quantifies viral load.

Comparative points:

- HBV serology provides multiple markers for staging infection; HCV requires molecular confirmation for active infection.
- IgM anti-HBc is specific for acute HBV; no direct equivalent exists for HCV.

Molecular Diagnostics

- **HBV DNA PCR:** Determines viral load, monitors therapy response, detects occult infection.
- **HCV RNA PCR:** Confirms active infection, monitors treatment efficacy.
- **Genotyping:** Critical for HCV treatment selection; HBV genotyping informs prognosis and resistance patterns.
- **Emerging methods:** Next-generation sequencing (NGS) allows precise viral characterization and detection of minority variants.

Imaging and Liver Assessment

Imaging techniques, including ultrasound, CT, and MRI, detect liver fibrosis, cirrhosis, and steatosis but cannot differentiate HBV from HCV. Non-invasive tools like elastography and FibroScan assess fibrosis severity. Imaging complements serological and molecular diagnostics by evaluating liver damage extent.

Comparative Analysis of HBV and HCV Diagnosis

Diagnostic Aspect	HBV	HCV
Serological markers	HBsAg, HBeAg, anti-HBc, anti-HBs	Anti-HCV antibodies
Molecular tests	HBV DNA	HCV RNA
Infection staging	Acute, chronic, resolved, occult	Active vs cleared infection
Vaccine	Available	Not available
Treatment guidance	Antivirals, monitoring cccDNA	DAAs, viral load-based therapy
Screening considerations	Vertical transmission, immunosuppressed	Blood transfusion, IV drug users

Discussion

Differentiating HBV and HCV is essential due to differences in transmission, chronicity, treatment, and preventive options. HBV allows staging using multiple serological markers; HCV relies heavily on molecular testing. In immunocompromised patients, HBV reactivation risk is high, necessitating prophylaxis, whereas HCV requires viremia monitoring and DAA therapy. International guidelines (EASL, AASLD) recommend universal screening for both viruses before immunosuppressive therapy or transfusion. Emerging diagnostic tools, including NGS and multiplex serological assays, enhance early detection and precise viral characterization. Clinicians should adopt a combined serological, molecular, and imaging-based approach for comprehensive assessment.

Conclusion. HBV and HCV share overlapping clinical features but differ in virology, serology, and molecular diagnostics. Integrated diagnostic strategies enable timely and accurate differentiation, guiding therapy selection and preventing complications. Knowledge of these differences is critical for effective patient management, especially in high-risk and immunocompromised populations.

References

1.S., Masharipova S., et al. "A Method for Obtaining Precipitating Serums for the Detection of Human Seminal Fluid Used in the Study of Physical Evidence in Forensic Biological Laboratories." *World Bulletin of Management and Law*, vol. 19, 7 Feb. 2023, pp. 42-44.

2. Машарипова, Ш. С., Ибрахимова, Х. Р., & Машарипов, С. М. (2023). Анализ эпидемиологических особенности диарейных заболеваний у детей южного приаралья. *O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI*, *2*(15), 884-887.

3. PATHOGENETIC PRINCIPLES OF ACUTE INFECTIOUS INTESTINAL INFECTIONS AND FEATURES OF CLINICAL COURSE AMONG CHILDREN OF DIFFERENT AGES. (2024). *Multidisciplinary Journal of Science and Technology*, *4*(2), 357-365. https://www.mjstjournal.com/index.php/mjst/article/view/877

4. Машарипова, Ш. С., Ибрахимова, Х. Р., & Машарипов, С. М. (2023). Анализ эпидемиологических особенности диарейных заболеваний у детей южного приаралья. *O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI*, *2*(15), 884-887.

5. Ибрахимова Хамида Рустамовна, Нурллаев Руслон Рустамбекович, & Артиков Икром Ахмеджанович (2020). ВЫЯВЛЕНИЕ ТУБЕРКУЛЕЗА В ХОРЕЗМСКОЙ ОБЛАСТИ. Наука и образование сегодня, (6-1 (53)), 83-84. doi: 10.24411/2414-5718-2020-10602

6. PATHOGENETIC PRINCIPLES OF ACUTE INFECTIOUS INTESTINAL INFECTIONS AND FEATURES OF CLINICAL COURSE AMONG CHILDREN OF DIFFERENT AGES. (2024). *Multidisciplinary Journal of Science and Technology*, *4*(2), 357-365. https://www.mjstjournal.com/index.php/mjst/article/view/877

7. Аскарова, Р. И., Юсупов, Ш. Р., & Ибрахимова, Х. Р. (2020). Анализ причин развития туберкулеза у детей и подростков. *Главный редактор–ЖА РИЗАЕВ*, *27*.

8. Ибрахимова, Х. Р., Отажанов, Ш. З., & Матякубова, О. У. (2019). ТУБЕРКУЛЕЗНЫЙ МЕНИНГИТ У БОЛЬНЫХ, ПРОЖИВАЮЩИХ В ХОРЕЗМСКОЙ ОБЛАСТИ. In *INTERNATIONAL SCIENTIFIC REVIEW OF THE PROBLEMS OF NATURAL SCIENCES AND MEDICINE* (pp. 96-104).

9. Ibraximova, H. R., Nurllayev, R. R., & Matyaqubova, O. U. (2023). KICHIK YOSHDAGI BOLALAR ORASIDA ICHAK PARAZITAR KASALLIKLARINING EPIDEMIOLOGIK XUSUSIYATLARI. *Новости образования: исследование в XXI веке*, *2*(15), 109-114.

10. Artikov, I. A., Sadullaev, S. E., Ibrakhimova, H. R., & Abdullayeva, D. K. (2023). *RELEVANCE OF VIRAL HEPATITIS EPIDEMIOLOGY. IMRAS, 6 (7), 316–322*.

11. Artikov, I. A., Sadullaev, S. E., Ibrakhimova, H. R., & Abdullayeva, D. K. (2023). *RELEVANCE OF VIRAL HEPATITIS EPIDEMIOLOGY. IMRAS, 6 (7), 316–322*.

12. Ibrakhimova, H. R., Matyakubova, O. U., Sadullaev, S. E., & Abdullayeva, D. K. (2023). *HELMINTISES IN CHILDREN AMONG THE POPULATION IN UZBEKISTAN. IMRAS, 6 (7), 323–327*.

13. Ibrakhimova, H. R., Sh YS Artikov IA PARAZITAR KASALLIKLAR, and NATIJASIDA INSON ORGANIZMIDA KUZATILADAIGAN ALLERGIK HOLATLAR. "Новости образования: исследование в XXI веке.–2023." *T* 2: 97-102.

14. Ибрахимова, Х. Р., Матьякубова, О. У., Садуллаев, С. Э., & Абдуллаева, Д. К. (2023). ГЕЛЬМИНТЫ У ДЕТЕЙ СРЕДИ НАСЕЛЕНИЯ УЗБЕКИСТАНА. *IMRAS*, *6*(7), 323-327.

15. Ибрахимова, Х. Р. Машарипова Шохиста Собировна, Матякубова Айша Уриновна, & Артиков Икром Ахмеджанович (2023). *ИНФИЦИРОВАНИЕ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ ОТ ЖИВОТНЫХ В НЕБЛАГОПОЛУЧНЫХ ПО ТУБЕРКУЛЕЗУ ХОЗЯЙСТВАХ. Проблемы современной науки и образования,(7 (185))*, 48-53.